title: Is cytarabine required in the treatment of acute promyelocytic leukemia? Updated experience and review of the literature.
authors.affiliation: Service d'Hématologie clinique at the Assistance Publique-Hopitaux de Paris (AP-HP), Hopital Avicenne, 93009 Bobigny, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Adès
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine